Compare CFFN & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | NKTR |
|---|---|---|
| Founded | 1893 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2010 | 1996 |
| Metric | CFFN | NKTR |
|---|---|---|
| Price | $8.45 | $37.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 15 |
| Target Price | $9.50 | ★ $133.08 |
| AVG Volume (30 Days) | ★ 1.1M | 747.0K |
| Earning Date | 10-28-2026 | 11-12-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | $16,300,000.00 | ★ $307,711,000.00 |
| Revenue This Year | $7.98 | N/A |
| Revenue Next Year | $4.98 | $27.72 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | 6.54 | ★ 86.00 |
| 52 Week Low | $6.07 | $33.40 |
| 52 Week High | $9.26 | $109.00 |
| Indicator | CFFN | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 37.37 |
| Support Level | $8.43 | $35.61 |
| Resistance Level | $8.83 | $39.89 |
| Average True Range (ATR) | 0.21 | 1.66 |
| MACD | 0.03 | 0.96 |
| Stochastic Oscillator | 47.21 | 36.06 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.